ArticleOncotarget2017
Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- The value of artificial intelligence in the diagnosis of lung cancer: A systematic review and meta-analysis.PloS one · 2023Pooled it
- LINC01314 suppresses proliferation and invasion via epithelial-to-mesenchymal transition regulation in lung adenocarcinoma.Translational cancer research · 2025Article
- LINC01197 inhibits influenza A virus replication by serving as a PABPC1 decoy.Veterinary research · 2024Article
- Pyroptosis-related long-noncoding RNA signature predicting survival and immunotherapy efficacy in patients with lung squamous cell carcinoma.Clinical and experimental medicine · 2024Article
- Article
- Establishment of a prognostic model toward lung squamous cell carcinoma based on mPhysiological genomics · 2023Article
- A five-cuproptosis-related LncRNA Signature: predicting prognosis, assessing immune function & drug sensitivity in lung squamous cell carcinoma.Journal of Cancer · 2023Article
- A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma.Annals of medicine · 2023Article
- GATA6-AS1 via Sponging miR-543 to Regulate PTEN/AKT Signaling Axis Suppresses Cell Proliferation and Migration in Gastric Cancer.Mediators of inflammation · 2023Article
- Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB.Frontiers in genetics · 2023Article
- An innovative systematic approach introduced the involved lncRNA-miR-mRNA network in cell cycle and proliferation after conventional treatments in breast cancer patients.Cell cycle (Georgetown, Tex.) · 2022Article
- Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma.Frontiers in pharmacology · 2022Article
- Analysis of LINC01314 and miR-96 Expression in Colorectal Cancer Patients via Tissue Microarray-Based FluorescenceDisease markers · 2022Article
- LINC01272 Suppressed Cell Multiplication and Induced Apoptosis Via Regulating MiR-7-5p/CRLS1 Axis in Lung Cancer.Journal of microbiology and biotechnology · 2021Article
- The Role of Sex-specific Long Non-coding RNAs in Cancer Prevention and Therapy.Journal of cancer prevention · 2021Review
- Long non-coding RNA GATA6-AS1 upregulates GATA6 to regulate the biological behaviors of lung adenocarcinoma cells.BMC pulmonary medicine · 2021Article
- Studies on host-foodborne bacteria in intestinal three-dimensional cell culture model indicate possible mechanisms of interaction.World journal of microbiology & biotechnology · 2021Article
- Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer.Frontiers in oncology · 2021Article
- Long Non-Coding RNA LINC01572 Promotes Hepatocellular Carcinoma ProgressionFrontiers in cell and developmental biology · 2021Article
- A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (LUSC) accounts for a significant proportion of lung cancer and there have been few therapeutic alternatives for recurrent LUSC due to the lack of specific driver molecules. To investigate the prospective role of lncRNAs in the tumorigenesis and progression of LUSC, the aberrantly expressed lncRNAs were calculated based on The Cancer Genome Atlas RNA-seq data. Of 7589 lncRNAs with 504 LUSC cases, 884 lncRNAs were identified as being aberrantly expressed (|log2 fold change| >2 and adjusted P<0.05) by DESeq R. The top 10 lncRNAs with the highest diagnostic value were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.